Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rubesent Syrup
- Development stage
- Unknown
- Lead developer
- Avogadro
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rubesent Syrup is an approved oral iron supplement syrup developed and marketed by the Indian pharmaceutical company Avogadro. Each 5ml dose of the syrup contains ferric di-pyrophosphate (equivalent to 10mg of elemental iron) and folic acid (25mcg) as its active ingredients. It is indicated for the prevention and treatment of iron deficiency anemia (IDA) associated with nutritional deficiencies. The formulation works by replenishing iron and folate levels in the body, which are essential cofactors for hemoglobin synthesis and healthy red blood cell production, thereby alleviating symptoms of tiredness and weakness.
- Brand names
- Rubesent SypRubesent Syrup
- Other names
- ferric di-pyrophosphate + folic acidferric pyrophosphate + folic acid
02
Targets
DHFR (Dihydrofolate reductase)FOLR1 (FRα)
Beyond the preview
Go deeper on Rubesent Syrup.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rubesent Syrup.